The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Dopamine in schizophrenia: a review and reconceptualization
Abstract
OBJECTIVE: The initial hypothesis that schizophrenia is a manifestation of hyperdopaminergia has recently been faulted. However, several new findings suggest that abnormal, although not necessarily excessive, dopamine activity is an important factor in schizophrenia. The authors discuss these findings and their implications. METHOD: All published studies regarding dopamine and schizophrenia and all studies on the role of dopamine in cognition were reviewed. Attention has focused on post-mortem studies, positron emission tomography, neuroleptic drug actions, plasma levels of the dopamine metabolite homovanillic acid (HVA), and cerebral blood flow. RESULTS: Evidence, particularly from intracellular recording studies in animals and plasma HVA measurements, suggests that neuroleptics act by reducing dopamine activity in mesolimbic dopamine neurons. Post-mortem studies have shown high dopamine and HVA concentrations in various subcortical brain regions and greater than normal dopamine receptor densities in the brains of schizophrenic patients. On the other hand, the negative/deficit symptom complex of schizophrenia may be associated with low dopamine activity in the prefrontal cortex. Recent animal and human studies suggest that prefrontal dopamine neurons inhibit subcortical dopamine activity. The authors hypothesize that schizophrenia is characterized by abnormally low prefrontal dopamine activity (causing deficit symptoms) leading to excessive dopamine activity in mesolimbic dopamine neurons (causing positive symptoms). CONCLUSIONS: The possible co-occurrence of high and low dopamine activity in schizophrenia has implications for the conceptualization of dopamine's role in schizophrenia. It would explain the concurrent presence of negative and positive symptoms. This hypothesis is testable and has important implications for treatment of schizophrenia and schizophrenia spectrum disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Multiple receptors for dopamine
Kebabian, J. W., & Calne, D. B. (1979) · Nature · doi:10.1038/277093a0 · Cited by 3,725
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Effects of Different Brain Lesions on Card Sorting: The Role of the Frontal Lobes
MILNER, B. (1963) · Archives of Neurology · doi:10.1001/archneur.1963.00460070100010 · Cited by 2,217
Society for Neuroscience 2007 abstracts
Wishart, T. M., Paterson, J. M., Short, D. M., Meredith, S., Robertson, K., Sutherland, C. D., Cousin, M. A., Dutia, M. B., & Gillingwater, T. H. (2007) · Cited by 2,094
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,019
Van Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014
Negative v Positive Schizophrenia: Definition and Validation
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,012
Swanson, L. W. (1982) · Brain Research Bulletin · doi:10.1016/0361-9230(82)90145-9 · Cited by 1,718
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
Sunahara, R. K., Guan, H.-C., O'Dowd, B. F., Seeman, P., Laurier, L. G., Ng, G., George, S. R., Torchia, J., Van Tol, H. H. M., & Niznik, H. B. (1991) · Nature · doi:10.1038/350614a0 · Cited by 1,165
Cloning and expression of a rat D2 dopamine receptor cDNA
Bunzow, J. R., Tol, H. H. M. V., Grandy, D. K., Albert, P., Salon, J., Christie, M., Machida, C. A., Neve, K. A., & Civelli, O. (1988) · Nature · doi:10.1038/336783a0 · Cited by 1,117
Positron Emission Tomography Reveals Elevated D 2 Dopamine Receptors in Drug-Naive Schizophrenics
Wong, D. F., Wagner, H. N., Tune, L. E., Dannals, R. F., Pearlson, G. D., Links, J. M., Tamminga, C. A., Broussolle, E. P., Ravert, H. T., Wilson, A. A., et al. (1986) · Science · doi:10.1126/science.2878495 · Cited by 932
Chiodo, L., & Bunney, B. (1983) · The Journal of Neuroscience · doi:10.1523/jneurosci.03-08-01607.1983 · Cited by 680
ABNORMALITIES OF CEREBRAL BLOOD FLOW DISTRIBUTION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA
Ingvar, D. H., & Franzén, G. (1974) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1974.tb09707.x · Cited by 665
Weinberger, D. R. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800310013001 · Cited by 603
The dopamine D2 receptor: two molecular forms generated by alternative splicing.
Dal Toso, R., Sommer, B., Ewert, M., Herb, A., Pritchett, D. B., Bach, A., Shivers, B. D., & Seeburg, P. H. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08585.x · Cited by 600
Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity
Bunney, B. S., & Grace, A. A. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90471-x · Cited by 549
Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats
Pycock, C. J., Kerwin, R. W., & Carter, C. J. (1980) · Nature · doi:10.1038/286074a0 · Cited by 549
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.12.1518 · Cited by 541
Farde, L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150013003 · Cited by 530
INCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA
Owen, F., Crow, T. J., Poulter, M., Cross, A. J., Longden, A., & Riley, G. J. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91740-3 · Cited by 518
Pharmacology of mesocortical dopamine neurons.
Bannon, M. J., & Roth, R. H. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06572-x · Cited by 488
Cloning of the cDNA and gene for a human D2 dopamine receptor.
Grandy, D. K., Marchionni, M. A., Makam, H., Stofko, R. E., Alfano, M., Frothingham, L., Fischer, J. B., Burke-Howie, K. J., Bunzow, J. R., & Server, A. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.9762 · Cited by 486
Recovery from the passage of an iron bar through the head
Harlow, J. M., & Miller, E. (1993) · History of Psychiatry · doi:10.1177/0957154x9300401406 · Cited by 432
Some cognitive effects of frontal-lobe lesions in man
Milner, B. A. (1982) · Philosophical Transactions of the Royal Society of London. B, Biological Sciences · doi:10.1098/rstb.1982.0083 · Cited by 426
Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia
Reynolds, G. P. (1983) · Nature · doi:10.1038/305527a0 · Cited by 415
Human brain dopamine receptors in children and aging adults
Seeman, P., Bzowej, N. H., Guan, H. ‐., Bergeron, C., Becker, L. E., Reynolds, G. P., Bird, E. D., Riederer, P., Jellinger, K., Watanabe, S., et al. (1987) · Synapse · doi:10.1002/syn.890010503 · Cited by 404
Increased Brain Dopamine and Dopamine Receptors in Schizophrenia
Mackay, A. V. P. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290090001001 · Cited by 397
The Role of Serotonin in Schizophrenia
Bleich, A., Brown, S.-L., Kahn, R., & van Praag, H. M. (1988) · Schizophrenia Bulletin · doi:10.1093/schbul/14.2.297 · Cited by 371
Mesulam, M. ‐. (1986) · Annals of Neurology · doi:10.1002/ana.410190403 · Cited by 363
Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?
Matthysse, S. (1973) · PubMed · Cited by 341
Pickar, D. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800070059008 · Cited by 318
SEEMAN, P. (1987) · Neuropsychopharmacology · doi:10.1016/0893-133x(87)90004-2 · Cited by 316
The Risks and Benefits of Clozapine versus Chlorpromazine
CLAGHORN, J., HONIGFELD, G., ABUZZAHAB, F. S., WANG, R., STEINBOOK, R., TUASON, V., & KLERMAN, G. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198712000-00002 · Cited by 301
Central neurotransmitters and aging
Pradhan, S. N. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90172-1 · Cited by 295
No D2 Receptor Increase in PET Study of Schizophrenia
Farde, L. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190091013 · Cited by 293
DISTRIBUTION OF CEREBRAL ACTIVITY IN CHRONIC SCHIZOPHRENIA
Ingvar, D., & Franzén, G. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90221-9 · Cited by 292
PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride
Farde, L., Halldin, C., Stone-Elander, S., & Sedvall, G. (1987) · Psychopharmacology · doi:10.1007/bf00210831 · Cited by 283
Daniel, D., Weinberger, D., Jones, D., Zigun, Jr., Coppola, R., Handel, S., Bigelow, L., Goldberg, T., Berman, K., & Kleinman, J. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-07-01907.1991 · Cited by 277
Bird, E., Barnes, J., Iversen, L., Spokes, E., Mackay, A. P., & Shepherd, M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91542-2 · Cited by 256
Neurotransmitter Receptors in Frontal Cortex of Schizophrenics
Bennett, J. P. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780090013001 · Cited by 248
Pickar, D., Labarca, R., Linnoila, M., Roy, A., Hommer, D., Everett, D., & Paul, S. M. (1984) · Science · doi:10.1126/science.6474162 · Cited by 246
Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings
Crow, T. J., Baker, H. F., Cross, A. J., Joseph, M. H., Lofthouse, R., Longden, A., Owen, F., Riley, G. J., Glover, V., & Killpack, W. S. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.3.249 · Cited by 213
Bacopoulos, N. G., Hattox, S. E., & Roth, R. H. (1979) · European Journal of Pharmacology · doi:10.1016/0014-2999(79)90175-4 · Cited by 212
Plasma Homovanillic Acid as a Predictor of Response to Neuroleptics
Davila, R. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800300060007 · Cited by 203
White, F. J., & Wang, R. Y. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90088-2 · Cited by 200
Chiodo, L., & Bunney, B. (1985) · The Journal of Neuroscience · doi:10.1523/jneurosci.05-09-02539.1985 · Cited by 195
The mesocortico-prefrontal dopaminergic neurons
Glowinski, J., Tassin, J. P., & Thierry, A. M. (1984) · Trends in Neurosciences · doi:10.1016/s0166-2236(84)80145-9 · Cited by 192
Toru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio, H., Ichikawa, H., Kurumaji, A., Takashima, M., Mataga, N., et al. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06312.x · Cited by 191
Dopamine deficiency in the cerebral cortex in Parkinson disease
Scatton, B., Rouquier, L., Javoy-Agid, F., & Agid, Y. (1982) · Neurology · doi:10.1212/wnl.32.9.1039 · Cited by 183
Plasma Homovanillic Acid Concentration and the Severity of Schizophrenic Illness
Davis, K. L., Davidson, M., Mohs, R. C., Kendler, K. S., Davis, B. M., Johns, C. A., DeNigris, Y., & Horvath, T. B. (1985) · Science · doi:10.1126/science.3975630 · Cited by 182
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.1.44 · Cited by 172
Cross, A. J., Crow, T. J., & Owen, F. (1981) · Psychopharmacology · doi:10.1007/bf00432676 · Cited by 164
Davidson, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800300057006 · Cited by 153
Plasma catecholamine metabolites and early response to haloperidol.
Mb, B., Swigar, M. E., JATLOW, P. I., et al. (1984) · PubMed · Cited by 146
Dopamine receptor subtype imbalance in schizophrenia
Hess, E. J., Bracha, H. S., Kleinman, J. E., & Creese, I. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90381-x · Cited by 139
Cortical modulation of striatal function
Scatton, B., Worms, P., Lloyd, K. G., & Bartholini, G. (1982) · Brain Research · doi:10.1016/0006-8993(82)90277-3 · Cited by 133
A family history study of schizophrenia-related personality disorders
Kendler, K. S., Masterson, C. C., Ungaro, R., & Davis, K. L. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.3.424 · Cited by 130
Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
Richelson, E. (1984) · PubMed · Cited by 127
Cohen, B. M., & Lipinski, J. F. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90111-6 · Cited by 125
van Kammen, D. P., Mann, L. S., Sternberg, D. E., Scheinin, M., Ninan, P. T., Marder, S. R., van Kammen, W. B., Rieder, R. O., & Linnoila, M. (1983) · Science · doi:10.1126/science.6133351 · Cited by 123
Brain Organization in Schizophrenia
Volkow, N. D., Brodie, J. D., Wolf, A. P., Gomez-Mont, F., Cancro, R., Gelder, P. V., Russell, J. A. G., & Overall, J. E. (1986) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1986.77 · Cited by 111
Relationship of Schizotypal Personality Disorder to Schizophrenia: Genetics
Torgersen, S. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.4.554 · Cited by 108
Hand, T. H., Hu, X., & Wang, R. Y. (1987) · Brain Research · doi:10.1016/0006-8993(87)90207-1 · Cited by 107
Pickar, D., Breier, A., Hsiao, J. K., Doran, A. R., Wolkowitz, O. M., Pato, C. N., Konicki, P. E., & Potter, W. Z. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810190041006 · Cited by 106
Bacopoulos, N. C., SPOKES, E. G. S., Bird, E. D., & Roth, R. H. (1979) · Science · doi:10.1126/science.38504 · Cited by 101
Nybäck, H., Berggren, B.-M., Hindmarsh, T., Sedvall, G., & Wiesel, F. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90003-3 · Cited by 98
Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients
Wolkowitz, O. M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800310072009 · Cited by 93
Rupniak, N. M. J., Hall, M. D., Mann, S., et al. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90577-5 · Cited by 93
The Major Dopamine D2 Receptor: Molecular Analysis of the Human D2 A Subtype
SELBIE, L. A., Hayes, G. R., & Shine, J. (1989) · DNA · doi:10.1089/dna.1.1989.8.683 · Cited by 92
Elsworth, J. D., Leahy, D. J., Roth, R. H., & Redmond, D. E. (1987) · Journal of Neural Transmission · doi:10.1007/bf01244639 · Cited by 91
An example of European multicenter trials: multispectral analysis of clozapine.
Fischer-Cornelssen, K. A., & Uj, F. (1976) · PubMed · Cited by 91
Loss of social group affinity following prefrontal lesions in free-ranging macaques
Myers, R. E., Swett, C., & Miller, M. (1973) · Brain Research · doi:10.1016/0006-8993(73)90182-0 · Cited by 90
Karoum, F. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190020003 · Cited by 80
Maturation of prefrontal cortex in the monkey revealed by local reversible cryogenic depression
Goldman, P. S., & Alexander, G. E. (1977) · Nature · doi:10.1038/267613a0 · Cited by 79
Methylphenidate challenge as a predictor of relapse in schizophrenia
Lieberman, J. A., Kane, J. M., Gadaleta, D. J., Brenner, R., LESSER, M., & Kinon, B. J. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.5.633 · Cited by 78
Leccese, A. P., & Lyness, W. H. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90091-8 · Cited by 70
The effect of apomorphine on regional cerebral blood flow in schizophrenia
Daniel, D. G., Berman, K. F., & Weinberger, D. R. (1989) · Journal of Neuropsychiatry · doi:10.1176/jnp.1.4.377 · Cited by 70
Rupniak, N. M. J., Kilpatrick, G. J., Hall, M. D., et al. (1984) · Psychopharmacology · doi:10.1007/bf00431458 · Cited by 69
Seeger, T., Thal, L. J., & Gardner, E. L. (1982) · Psychopharmacology · doi:10.1007/bf00435275 · Cited by 67
van Kammen, D. P., Docherty, J. P., & Bunney, W. E. (1982) · PubMed · Cited by 66
Wachtel, S. R., & White, F. J. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24245-8 · Cited by 64
L-dopa challenge and relapse in schizophrenia
Davidson, M., Keefe, R. S. E., Mohs, R. C., Siever, L. J., LOSONCZY, M. F., Horvath, T., & Davis, K. L. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.7.934 · Cited by 62
In Freud's Shadow: Adler in Context
Lieberman, E. J. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.12.1633 · Cited by 61
Dopamine metabolism increases in post-mortem schizophrenic basal ganglia
Toru, M., Nishikawa, T., Mataga, N., & Takashima, M. (1982) · Journal of Neural Transmission · doi:10.1007/bf01254928 · Cited by 57
Davidson, M., Kahn, R. S., Powchik, P., Warne, P., Losonczy, M. F., Kaminsky, R., Apter, S., Jaff, S., & Davis, K. L. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810250075011 · Cited by 57
Control of exogenous factors affecting plasma homovanillic acid concentration
Davidson, M., Giordano, A. B., Mohs, R. C., et al. (1987) · Psychiatry Research · doi:10.1016/0165-1781(87)90091-6 · Cited by 57
Jaskiw, G. E., Weinberger, D. R., & Crawley, J. N. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90144-b · Cited by 57
Doran, A. R., Boronow, J., Weinberger, D. R., Wolkowitz, O. M., Breier, A., & Pickar, D. (1987) · Neuropsychopharmacology · doi:10.1016/0893-133x(87)90006-6 · Cited by 54
Plasma catecholamine metabolites and treatment response at neuroleptic steady state
Bowers, M. B., Swigar, M. E., Jatlow, P. I., et al. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90245-x · Cited by 49
Amphetamine response and relapse risk after depot neuroleptic discontinuation
ANGRIST, B. M., Peselow, E. D., Rubinstein, M. E., Wolkin, A., & Rotrosen, J. (1985) · Psychopharmacology · doi:10.1007/bf00428187 · Cited by 49
Kopin, I. J. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90003-6 · Cited by 47
Glazer, W. M., Bowers, M. B., Charney, D. S., & Heninger, G. R. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90034-6 · Cited by 43
Todd, R. D., Khurana, T. S., Sajovic, P., Stone, K. R., & O’Malley, K. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10134 · Cited by 41
Keyser, J. D., Backer, J. D., Ebinger, G., & Vauquelin, G. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90041-3 · Cited by 34
Jenner, P. G., Rupniak, N. M. J., & MARSDEN, C. D. (1985) · Psychopharmacology series · doi:10.1007/978-3-642-70140-5_21 · Cited by 32
A Critical Appraisal of CSF Monoamine Metabolite Studies in Schizophrenia
Widerlöv, E. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb42115.x · Cited by 31
Kirch, D. G., Jaskiw, G. E., Linnoila, M., Weinberger, D. R., & Wyatt, R. J. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90094-7 · Cited by 31
Cited by
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
“Further evidence came from postmortem studies that showed abnormalities in dopaminergic indexes in schizophrenia, although the interpretation of these data was always confounded by drug effects (1, 3).”
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
The neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1991-11-01
- Volume
- 148
- Issue
- 11
- Pages
- 1474-1486
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2151331628
- Cited by
- 2,018
- References
- 101
- FWCI
- 37.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.